JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
A common disease worldwide is known as atopic dermatitis (AD), named also as atopic eczema, which is a chronic recurrent complex inflammatory skin disorder. It affects 2–10% of the adult population and up to 20% of the pediatric population. The clinical AD picture appears in typically localized ecze...
Main Authors: | Krzysztof Szalus, Magdalena Trzeciak, Roman J. Nowicki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/8/11/1743 |
Similar Items
-
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01) -
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
by: Michelle Le, et al.
Published: (2021-09-01) -
The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
by: Napolitano M, et al.
Published: (2021-03-01) -
Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
by: Jannett Nguyen, MD, et al.
Published: (2021-01-01) -
Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
by: Napolitano M, et al.
Published: (2020-01-01)